A Mathematical Model of a Zn/Br2 Cell on Charge

A mathematical model of a parallel plate electrochemical cell with a separator and a homogeneous bulk reaction is presented. The model is based on the Zn/Br2 redox couple and can be used as an aid for the design of an efficient rechargeable storage battery. It is shown that four independent variables exist for the system at a fixed temperature: the effective separator thickness, the residence time, the channel width, and the potential driving force. Performance criteria of interest for the Zn/Br2 battery are defined. Predictions of performance during the charging process are presented. It is shown that the cell performance improves as the effective thickness of the separator is increased, despite the associated greater cell resistance. It is also shown that a change in the residence time has little effect on cell performance

Parallel Plate Electrochemical Reactor Model: Material Balance Closure and a Simplification

A material balance closure calculation is presented to test the consistency of a previously published model of a parallelplate electrochemical reactor. New expressions are used in this procedure to calculate the average concentration of species i and the average current density for reaction j from the predicted concentration and potential distributions. Also, the previously presented model equations are simplified by assuming that the axial concentration gradient for species i can be approximated by a step change from the known feed concentration to the unknown outlet concentration. This one-step model provides a qualitative evaluation of cell performance and adds insight into understanding of the previous model, while providing substantial savings in computer time. The models are compared using a hypothetical case of the electrowinning of copper from a chloride solution. For a small aspect ratio (S/L), the models show that a set of independent variables consists of the cell potential (Ecell), the surface area of an electrode per unit of cell volume(1/S), and the residence time (L/avg) when the feed concentrations (ci,feed) are fixed

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination

Sports-related concussions (SRC) have developed into a highly discussed topic in sports medicine over the last few years and demonstrate a severe issue in the personalized treatment of patients. This retrospective cohort study investigated 86 patients with sports-related concussions in a level 1 trauma center, relating to the mechanism, symptoms, medical history, acute therapy including first assessment and the return to sport. The research is based on medical records as well as questionnaires six months after hospitalization. Loss of consciousness for under 30 min (41.2%), headache (36.5%) and amnesia (29.4%) were the most frequent symptoms when presenting in the emergency room. During the hospitalization, mainly headache and vertigo were documented. Most concussions occurred after incidents in equitation and cycling sports; the most common mechanism was falling to the ground with a subsequent impact (59.3%). At the time of discharge from hospital, in 13.4% of all cases, concussion symptoms were still documented in medical records, in contrast to 39.5% of the concerned athletes who reported symptoms for longer than 24 h, and 41.0% who reported ongoing post-concussion symptoms after six months. Concussions are difficult-to-treat disorders with a challenging diagnostic process and many symptoms in various values and levels of persistence. Therefore, a patient-involving treatment with a complaint-dependent return to sport process should be applied to concerned athletes

Optical photometry and X-ray monitoring of the "Cool Algol" BD+05 706: Determination of the physical properties

We present new photometric observations in the BVRI bands of the double-lined eclipsing binary BD+05 706 conducted over three observing seasons, as well as new X-ray observations obtained with the ROSAT satellite covering a full orbital cycle (P = 18.9 days). A detailed light-curve analysis of the optical data shows the system to be semidetached, confirming indications from an earlier analysis by Torres et al. (1998), with the less massive and cooler star filling its Roche lobe. The system is a member of the rare class of cool Algol systems, which are different from the "classical" Algol systems in that the mass-gaining component is also a late-type star rather than a B- or A-type star. By combining the new photometry with a reanalysis of the spectroscopic observations reported by Torres et al. (1998) we derive accurate absolute masses for the components of M1 = 2.633 +/- 0.028 Msun and M2 = 0.5412 +/- 0.0093 Msun, radii of R1 = 7.55 +/- 0.20 Rsun and R2 = 11.02 +/- 0.21 Rsun, as well as effective temperatures of 5000 +/- 100 K and 4640 +/- 150 K for the primary and secondary, respectively. There are obvious signs of activity (spottedness) in the optical light curve of the binary. Our X-ray light curve clearly shows the primary eclipse but not the secondary eclipse, suggesting that the primary star is the dominant source of the activity in the system. The depth and duration of the eclipse allow us to infer some of the properties of the X-ray emitting region around that star.Comment: 38 pages including 8 figures and 11 tables. To appear in The Astronomical Journal, June 200

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Search for dark matter produced in association with bottom or top quarks in √s = 13 TeV pp collisions with the ATLAS detector

A search for weakly interacting massive particle dark matter produced in association with bottom or top quarks is presented. Final states containing third-generation quarks and miss- ing transverse momentum are considered. The analysis uses 36.1 fb−1 of proton–proton collision data recorded by the ATLAS experiment at √s = 13 TeV in 2015 and 2016. No significant excess of events above the estimated backgrounds is observed. The results are in- terpreted in the framework of simplified models of spin-0 dark-matter mediators. For colour- neutral spin-0 mediators produced in association with top quarks and decaying into a pair of dark-matter particles, mediator masses below 50 GeV are excluded assuming a dark-matter candidate mass of 1 GeV and unitary couplings. For scalar and pseudoscalar mediators produced in association with bottom quarks, the search sets limits on the production cross- section of 300 times the predicted rate for mediators with masses between 10 and 50 GeV and assuming a dark-matter mass of 1 GeV and unitary coupling. Constraints on colour- charged scalar simplified models are also presented. Assuming a dark-matter particle mass of 35 GeV, mediator particles with mass below 1.1 TeV are excluded for couplings yielding a dark-matter relic density consistent with measurements

Research and Design of a Routing Protocol in Large-Scale Wireless Sensor Networks

无线传感器网络，作为全球未来十大技术之一，集成了传感器技术、嵌入式计算技术、分布式信息处理和自组织网技术，可实时感知、采集、处理、传输网络分布区域内的各种信息数据，在军事国防、生物医疗、环境监测、抢险救灾、防恐反恐、危险区域远程控制等领域具有十分广阔的应用前景。 本文研究分析了无线传感器网络的已有路由协议，并针对大规模的无线传感器网络设计了一种树状路由协议，它根据节点地址信息来形成路由，从而简化了复杂繁冗的路由表查找和维护，节省了不必要的开销，提高了路由效率，实现了快速有效的数据传输。 为支持此路由协议本文提出了一种自适应动态地址分配算——ADAR（AdaptiveDynamicAddre...As one of the ten high technologies in the future, wireless sensor network, which is the integration of micro-sensors, embedded computing, modern network and Ad Hoc technologies, can apperceive, collect, process and transmit various information data within the region. It can be used in military defense, biomedical, environmental monitoring, disaster relief, counter-terrorism, remote control of haz...学位：工学硕士院系专业：信息科学与技术学院通信工程系_通信与信息系统学号：2332007115216